Summary
Pfizer and its partner Eli Lilly announced positive phase 3 results treating patients with osteoarthritis of the knee or hip using tanezumab.
The positive phase 3 results with tanezumab in osteoarthritis will allow Pfizer to file for FDA approval in 2019.
A major opioid epidemic exists today, and new alternatives drugs such as tanezumab are desperately needed.
With the U.S. government in the process of passing a bill to help the opioid epidemic, there is a good chance that the FDA will be more lenient when it comes to FDA approvals for new pain drugs.
The biggest problem with opioids is that they have the potential to cause addiction, and only provide moderate improvement for pain.
This idea was discussed in more depth with members of my private investing community, Biotech Analysis Central.
Recently, Pfizer (PFE) and its partner Eli Lilly (LLY) announced positive phase 3 results for treating patients with osteoarthritis (NYSE:OA). The study met on all the endpoints, but the next item to see is how a safety study turns out in the near future. Based on the efficacy data, I believe that Pfizer is on to something good. Especially, when it has the possibility to provide pain relief for OA of the knee or hip without the need of using opioids. For that reason, I believe that Pfizer is a strong buy.
